Enveric Biosciences Inc (ENVB NASDAQ) stock market data APIs
$0.6333
-0.03(-4.7%)
as of October 24, 2025
Try our APIs with
free plan!
Enveric Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. The company is headquartered in Cambridge, Massachusetts.
Prev. Close
0.6333
Open
0.6047
High
0.6715
Low
0.6083
52 wk Range
0.561-123.75
Market Cap
3 906 K
Shares Outstanding
6 220 K
Revenue
35 405 K
EPS
-0.97
Beta
0.292
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Enveric Biosciences Inc data using free add-ons & libraries
Get Enveric Biosciences Inc Fundamental Data
Enveric Biosciences Inc Fundamental data includes:
- Net Revenue: 35 405 K
- EBITDA: -9 675 295
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-14
- EPS/Forecast: -0.35
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Enveric Biosciences Inc News
New
AbbVie ends in green six straight sessions of declines
[AbbVie] hapabapa AbbVie (NYSE:ABBV [https://seekingalpha.com/symbol/ABBV]) snapped six consecutive sessions of losses on Thursday as the stock ended 0.29% lower at $226.87. Since October 8, the sto...
AbbVie could face patent battle over depression asset gained in Gilgamesh deal
[Patent infringement] TheaDesign * Microcap Enveric Biosciences (NASDAQ:ENVB [https://seekingalpha.com/symbol/ENVB]) is threatening to take legal action against AbbVie (NYSE:ABBV [https://seekingal...
Enveric Biosciences hires Fish & Richardson to defend patent tied to AbbVie deal
Investing.com -- Enveric Biosciences (NASDAQ: ENVB) has hired prominent intellectual property law firm Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmac...
Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal
EB-003, Enveric’s lead product candidate, is protected by a different patent family that includes an issued U.S. patent and pending U.S. and international patents, all of which are separate and dist...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
